JP Morgan has expertly guided Ono Pharmaceutical in its strategic $2.4 billion acquisition of Deciphera Pharmaceuticals, a significant move in the biopharmaceutical industry focused on cancer treatment innovations.
This acquisition is a key part of Ono’s strategy to enhance its global oncology portfolio and expand its research and market presence, especially in the United States and Europe. Ono Pharmaceutical, a leading firm in the healthcare sector, agreed to
All the week’s industry events straight to your inbox.
By signing up you agree to our terms of use and privacy policy.
7 Bell Yard, London, England, WC2A 2JR
You will soon receive a Reset Password link
By signing up you agree to terms of use and privacy policy.
Continue with Facebook Continue with Google